Discover how cancer treatments impact heart health and learn strategies to mitigate cardiovascular risks during and after ...

The American Heart Association has released a statement detailing cardiometabolic considerations for survivors of childhood ...

Excited by strong phase II data, Novartis is exercising its option to license Akcea Therapeutics’ TQJ230, a treatment to reduce the risk of cardiovascular disease in people living with elevated ...

New research has uncovered a surprising culprit underlying cardiovascular diseases in obesity and diabetes -- not the presence of certain fats, but their suppression. The study challenges the ...

Low vitamin C levels are linked to higher cardiovascular disease prevalence in people with type 2 diabetes. Fresh fruit and ...

Romosozumab was not associated with increased cardiovascular risks among patients with osteoporosis when compared with bisphosphonate use. Romosozumab does not appear to significantly increase the ...

The "Drug Discovery Services Market by Process (Target Validation, Hit-to-Lead, Lead Optimization), Type (Chemistry, Biology), Therapeutic Area (Oncology, Neurology, Infectious, CVD), Drug Type (Small ...

Excited by strong phase II data, Novartis is exercising its option to license Akcea Therapeutics’ TQJ230, a treatment to reduce the risk of cardiovascular disease in people living with elevated ...